NCT05663879

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ID120040002 in Healthy Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 86 (estimated)
• Sponsor: IlDong Pharmaceutical Co Ltd · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A Randomized, Double-blinded, Partial-open, Placebo and Active-controlled, Single and Multiple Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ID120040002 in Healthy Volunteers

Detailed description

To evaluate the safety, tolerability, and pharmacokinetic characteristics and to explore pharmacodynamic characteristics and food effects after single and multiple doses of ID120040002 in healthy volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ID120040002	Drug: ID120040002
DRUG	Compound-X	Drug: Compound-X
DRUG	Placebo comparator	Placebo comparator

Timeline

• Start date: 2022-12-07
• Primary completion: 2023-07-31
• Completion: 2023-07-31
• First posted: 2022-12-23
• Last updated: 2022-12-23

Locations

1 site across 1 country: South Korea